The effects of age, sex and treatment with xamoterol on exercise capacity in patients with heart failure.
The influence of age, sex and xamoterol treatment on exercise capacity has been investigated in 705 heart failure patients who took part in a multicentre, placebo-controlled study. Regression analysis suggests that although less than 20% of the total variation in exercise capacity between patients is explained by these factors, useful information may be gained by taking them into account. Exercise capacity declines with age, more rapidly in males than in females; the benefits of xamoterol are independent of age and sex. This approach demonstrates that exercise testing is a sensitive indicator of physical performance and allows the effects of treatment to be seen in context.
France
L A
LA
ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
Green
F L
FL
Snow
H M
HM
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000375:Aging / Q000502:physiology*; D015444:Exercise; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000494:pharmacology*; D011897:Random Allocation; D012737:Sex Factors; D017307:Xamoterol
D000318:Adrenergic beta-Agonists; D011412:Propanolamines; D017307:Xamoterol